CO2018006714A2 - 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa - Google Patents
3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasaInfo
- Publication number
- CO2018006714A2 CO2018006714A2 CONC2018/0006714A CO2018006714A CO2018006714A2 CO 2018006714 A2 CO2018006714 A2 CO 2018006714A2 CO 2018006714 A CO2018006714 A CO 2018006714A CO 2018006714 A2 CO2018006714 A2 CO 2018006714A2
- Authority
- CO
- Colombia
- Prior art keywords
- azabicyclo
- hexanes
- substituted
- ketohexokinase inhibitors
- ketohexokinase
- Prior art date
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title abstract 4
- 102100023418 Ketohexokinase Human genes 0.000 title abstract 2
- 108010062852 Ketohexokinase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
En la presente se proporcionan 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa, procesos para la elaboración de estos compuestos, y métodos que comprenden administrar estos compuestos a un mamífero que lo necesita.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272598P | 2015-12-29 | 2015-12-29 | |
| US201662423549P | 2016-11-17 | 2016-11-17 | |
| PCT/IB2016/057728 WO2017115205A1 (en) | 2015-12-29 | 2016-12-16 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018006714A2 true CO2018006714A2 (es) | 2018-07-10 |
Family
ID=57755415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0006714A CO2018006714A2 (es) | 2015-12-29 | 2018-06-27 | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US9809579B2 (es) |
| EP (1) | EP3397631B1 (es) |
| JP (1) | JP6503515B2 (es) |
| KR (1) | KR102073048B1 (es) |
| CN (1) | CN108473469B (es) |
| AU (1) | AU2016380920B2 (es) |
| CA (1) | CA2952466A1 (es) |
| CL (1) | CL2018001667A1 (es) |
| CO (1) | CO2018006714A2 (es) |
| CU (1) | CU24540B1 (es) |
| CY (1) | CY1124389T1 (es) |
| DK (1) | DK3397631T3 (es) |
| EC (1) | ECSP18048517A (es) |
| ES (1) | ES2871251T3 (es) |
| GE (1) | GEP20207147B (es) |
| HR (1) | HRP20210769T1 (es) |
| HU (1) | HUE054380T2 (es) |
| IL (1) | IL260330B (es) |
| LT (1) | LT3397631T (es) |
| MA (1) | MA43518B1 (es) |
| MD (1) | MD3397631T2 (es) |
| MX (1) | MX376072B (es) |
| NI (1) | NI201800072A (es) |
| PE (1) | PE20181289A1 (es) |
| PH (1) | PH12018501375A1 (es) |
| PL (1) | PL3397631T3 (es) |
| PT (1) | PT3397631T (es) |
| RS (1) | RS61896B1 (es) |
| RU (1) | RU2696269C1 (es) |
| SG (1) | SG11201804363UA (es) |
| SI (1) | SI3397631T1 (es) |
| SV (1) | SV2018005709A (es) |
| TN (1) | TN2018000198A1 (es) |
| TW (1) | TWI653232B (es) |
| UA (1) | UA121271C2 (es) |
| UY (1) | UY37051A (es) |
| WO (1) | WO2017115205A1 (es) |
| ZA (1) | ZA201803449B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24540B1 (es) * | 2015-12-29 | 2021-08-06 | Pfizer | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa |
| EP3872080B1 (en) | 2016-09-02 | 2023-08-16 | Cyclerion Therapeutics, Inc. | Fused bicyclic sgc stimulators |
| US10558874B1 (en) | 2017-01-19 | 2020-02-11 | State Farm Mutual Automobile Insurance Company | Apparatuses, systems and methods for generation and transmission of vehicle operation mode data |
| CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
| TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Ｇｌｐ－１受體促效劑及其用途 |
| CR20210110A (es) | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| AU2020214064B2 (en) * | 2019-01-29 | 2022-10-20 | Shandong Xuanzhu Pharma Co., Ltd. | Hexone glucokinase inhibitor and use thereof |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN111978296A (zh) * | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| TWI750685B (zh) * | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| WO2021129737A1 (zh) | 2019-12-24 | 2021-07-01 | 南京明德新药研发有限公司 | 具有khk抑制作用的化合物 |
| CN114846008B (zh) * | 2019-12-25 | 2024-05-28 | 杭州中美华东制药有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| GB202001856D0 (en) * | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| US20230167087A1 (en) * | 2020-02-13 | 2023-06-01 | Eli Lilly And Company | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| TWI823072B (zh) | 2020-03-27 | 2023-11-21 | 美商輝瑞股份有限公司 | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 |
| CN115667244B (zh) * | 2020-04-20 | 2024-04-12 | 株式会社Lg化学 | 3-氮杂二环烷基衍生物及包含其的药物组合物 |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN113754640B (zh) * | 2020-06-03 | 2023-02-14 | 山东轩竹医药科技有限公司 | 氘代的己酮糖激酶抑制剂及其用途 |
| WO2022022476A1 (zh) * | 2020-07-28 | 2022-02-03 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂的盐、晶型及其用途 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| US20240067633A1 (en) * | 2020-12-25 | 2024-02-29 | Sichuan Haisco Pharmaceutical Co., Ltd. | Ketohexokinase inhibitor and use thereof |
| US20230079863A1 (en) | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
| KR20220136939A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2022262841A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 一种螺环化合物的盐型、晶型及其制备方法 |
| US20250129057A1 (en) | 2021-08-31 | 2025-04-24 | Pfizer Inc. | Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt |
| CN115974851A (zh) * | 2021-10-14 | 2023-04-18 | 华领医药技术（上海）有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
| KR20230098069A (ko) * | 2021-12-24 | 2023-07-03 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| CN114315494B (zh) * | 2021-12-29 | 2023-09-22 | 苏州楚凯药业有限公司 | 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法 |
| US20250145619A1 (en) * | 2022-02-09 | 2025-05-08 | Youngene Therapeutics Co., Ltd | Khk inhibitor, preparation method therefor and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN119584994A (zh) | 2022-05-02 | 2025-03-07 | 普雷西里克斯公司 | 预靶向 |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| AR132416A1 (es) | 2023-04-12 | 2025-06-25 | Centennial Therapeutics Llc | Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa |
| WO2024249612A1 (en) | 2023-05-31 | 2024-12-05 | Centennial Therapeutics, Llc | Bicyclic compounds for ketohexokinase inhibition |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980350A (en) | 1988-02-25 | 1990-12-25 | Merck & Co., Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ES2318899T3 (es) | 1998-07-06 | 2009-05-01 | Bristol-Myers Squibb Company | Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina. |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| PL210793B1 (pl) | 2001-02-28 | 2012-03-30 | Merck & Co Inc | Acylowane pochodne piperydyny |
| IL163659A0 (en) | 2002-02-27 | 2005-12-18 | Pfizer Prod Inc | Acc inhibitors |
| AP2320A (en) | 2004-05-12 | 2011-11-07 | Pfizer Procucts Inc | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors. |
| EP1753766A1 (en) | 2004-05-25 | 2007-02-21 | Pfizer Products Inc. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008024902A2 (en) | 2006-08-23 | 2008-02-28 | University Of Florida Research Foundation, Inc. | Targeting of fructokinase as therapy for cardiovascular disease, metabolic syndrome, and renal disease |
| AP2009004880A0 (en) | 2006-11-29 | 2009-06-30 | Pfizer Prod Inc | Spiroketone acetyl-COA carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| ES2404580T3 (es) * | 2007-10-11 | 2013-05-28 | Glaxosmithkline Llc | Novedosos inhibidores de la ehs y uso de los mismos |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| US8318762B2 (en) | 2008-05-28 | 2012-11-27 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| US20120108565A1 (en) * | 2008-07-30 | 2012-05-03 | Lalima Sharma | Pyrrole carboxylic acid derivatives as antibacterial agents |
| RS52236B (en) | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
| CN102369197B (zh) | 2009-04-08 | 2013-11-06 | 埃科特莱茵药品有限公司 | 作为adp受体拮抗剂的6-(3-氮杂-二环[3.1.0]己-3-基)-2-苯基-嘧啶 |
| JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| MX2011013034A (es) | 2009-06-05 | 2012-02-08 | Pfizer | 1-(piperidin-4-yl)-pirazol derivados como moduladores de gpr 119. |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| KR101686913B1 (ko) * | 2009-08-13 | 2016-12-16 | 삼성전자주식회사 | 전자기기에서 이벤트 서비스 제공 방법 및 장치 |
| JP2013525370A (ja) * | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| US9387245B2 (en) | 2010-08-06 | 2016-07-12 | University Of Colorado, A Body Corporate | Methods and compositions for the inhibition of fructokinase |
| CN102432598A (zh) * | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| CN113057959B (zh) | 2014-02-11 | 2024-07-16 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶（KHK）iRNA组合物及其使用方法 |
| CU24540B1 (es) * | 2015-12-29 | 2021-08-06 | Pfizer | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa |
-
2016
- 2016-12-16 CU CU2018000046A patent/CU24540B1/es unknown
- 2016-12-16 PL PL16823054T patent/PL3397631T3/pl unknown
- 2016-12-16 RU RU2018123528A patent/RU2696269C1/ru active
- 2016-12-16 SG SG11201804363UA patent/SG11201804363UA/en unknown
- 2016-12-16 SI SI201631206T patent/SI3397631T1/sl unknown
- 2016-12-16 WO PCT/IB2016/057728 patent/WO2017115205A1/en active Application Filing
- 2016-12-16 KR KR1020187018089A patent/KR102073048B1/ko active Active
- 2016-12-16 TN TNP/2018/000198A patent/TN2018000198A1/en unknown
- 2016-12-16 HU HUE16823054A patent/HUE054380T2/hu unknown
- 2016-12-16 JP JP2018533924A patent/JP6503515B2/ja active Active
- 2016-12-16 US US15/381,295 patent/US9809579B2/en active Active
- 2016-12-16 MA MA43518A patent/MA43518B1/fr unknown
- 2016-12-16 UA UAA201807242A patent/UA121271C2/uk unknown
- 2016-12-16 MD MDE20181083T patent/MD3397631T2/ro not_active IP Right Cessation
- 2016-12-16 PT PT168230548T patent/PT3397631T/pt unknown
- 2016-12-16 GE GEAP201614820A patent/GEP20207147B/en unknown
- 2016-12-16 EP EP16823054.8A patent/EP3397631B1/en active Active
- 2016-12-16 PE PE2018001204A patent/PE20181289A1/es unknown
- 2016-12-16 RS RS20210654A patent/RS61896B1/sr unknown
- 2016-12-16 LT LTEP16823054.8T patent/LT3397631T/lt unknown
- 2016-12-16 MX MX2018007755A patent/MX376072B/es active IP Right Grant
- 2016-12-16 CN CN201680077234.3A patent/CN108473469B/zh active Active
- 2016-12-16 AU AU2016380920A patent/AU2016380920B2/en active Active
- 2016-12-16 HR HRP20210769TT patent/HRP20210769T1/hr unknown
- 2016-12-16 ES ES16823054T patent/ES2871251T3/es active Active
- 2016-12-16 DK DK16823054.8T patent/DK3397631T3/da active
- 2016-12-22 CA CA2952466A patent/CA2952466A1/en active Pending
- 2016-12-27 UY UY0001037051A patent/UY37051A/es not_active Application Discontinuation
- 2016-12-28 TW TW105143483A patent/TWI653232B/zh active
-
2017
- 2017-10-11 US US15/729,885 patent/US10174007B2/en active Active
-
2018
- 2018-05-24 ZA ZA2018/03449A patent/ZA201803449B/en unknown
- 2018-06-13 SV SV2018005709A patent/SV2018005709A/es unknown
- 2018-06-19 CL CL2018001667A patent/CL2018001667A1/es unknown
- 2018-06-25 NI NI201800072A patent/NI201800072A/es unknown
- 2018-06-26 PH PH12018501375A patent/PH12018501375A1/en unknown
- 2018-06-27 EC ECSENADI201848517A patent/ECSP18048517A/es unknown
- 2018-06-27 CO CONC2018/0006714A patent/CO2018006714A2/es unknown
- 2018-06-28 IL IL260330A patent/IL260330B/en unknown
- 2018-12-06 US US16/211,283 patent/US20190106412A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/744,283 patent/US10787438B2/en active Active
- 2020-08-21 US US16/999,295 patent/US10988463B2/en active Active
-
2021
- 2021-03-23 US US17/209,780 patent/US11634410B2/en active Active
- 2021-05-06 CY CY20211100385T patent/CY1124389T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MX2017006283A (es) | Peptidos macrociclicos utiles como inmunomoduladores. | |
| UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| GT201500247A (es) | Imidazopiridazinas sustituidas | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| BR112017008481A2 (pt) | composto antimicótico | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
| BR112017011685A2 (pt) | composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| EP3357960A4 (en) | RESIN ADDITIVE AND MASTERBATCH AND RESIN COMPOSITION THEREOF | |
| EA201800348A1 (ru) | Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
| CO6680630A2 (es) | Composición fungicida sinérgica |